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Abstract: Despite the high safety profile of peptide-based vaccines over conventional counterparts, 
the inability of small peptides to produce a strong immune response represents the main obstacle for 
the development of these types of vaccines. Introducing a self-adjuvanting moiety such as poly  
tert-butyl acrylate can overcome this problem. However, the mode of action of this polymer to 
produce the desired humoral and/or cellular immune response is still unknown. An AlphaScreen 
assay along with the cell-free expression technique were employed to evaluate the affinity of this 
polymer toward toll-like receptor 2 (TLR2) for stimulation of innate immunity. In this study, B-cell 
epitope, J14, derived from the M protein of group A streptococcus (GAS) was used in conjugation 
with the poly tert-butyl acrylate as well as a biotin moiety. Pam2Cys analogue, the potent TLR2 
agonist, was synthesized and used as a positive control in this work. The AlphaScreen assay showed 
the inability of polymer to bind to TLR2, while the Pam2Cys displayed very strong binding to TLR2 
as expected. This result indicated that poly tert-butyl acrylate does not express its immunogenic 
effects through recognition by TLR2 and therefore further studies are required to determine its mode 
of action. 
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1. Introduction 
Peptide-based vaccines can be used to avoid the drawbacks of conventional or protein-based 
vaccines. These drawbacks include toxicity, allergy and autoimmune responses triggered by 
immunization [1]. For example, using the whole pathogen group A streptococcus (GAS) or its 
membrane protein, M protein, as an antigen in vaccine development can cause rheumatic heart 
disease due to the similarity of the antigen and heart protein [2,3]. The use of a small M protein-
derived peptide sequence, J14 epitope, as an antigen in peptide-based vaccine did not cause this 
autoimmune complication [4]. However, peptide alone cannot produce a strong immune response. 
Therefore, incorporating an immunestimulant compound, adjuvant, with the peptide is essential to 
obtain the desired immune response against the antigen. The toxicity and low number of available 
licensed adjuvants directed the attention of scientists to find new ways to overcome this problem. In 
our laboratory, poly tert-butyl acrylate was used for the first time as a self-adjuvanting molecule in a 
chemical conjugation with antigens [5]. We proved the ability of this polymer to trigger the humoral 
immune system to produce IgG antibodies and to activate cellular immunity through the activation of 
CD8
+
 T cells. For example, a series of poly tert-butyl acrylate-J14 vaccine candidates were able to 
induce strong antibody production [6,7], which were able to opsonize GAS [8]. Also, poly tert-butyl 
acrylate conjugated with E744–57 epitope, derived from the human papilloma virus (HPV) 16 E7 
protein, displayed a high efficacy as a therapeutic vaccine to eradicate tumor cells in vivo [9–12]. 
Toll-like receptors (TLRs) play an important role to link the innate and adaptive immunity as 
the activation of these transmembrane proteins leads to stimulation of both humoral and cellular 
immunity [13–15]. TLR2 is an important receptor that can be targeted by many microbial 
components such as lipopeptides, lipoarabinomannans, lipomannans, glycosylphosphatidylinositol, 
lipoteichoic acid, and a range of proteins including lipoproteins and glycoproteins, zymosan and 
peptidoglycan (56–60 kDa) [16–20]. Mixing or direct conjugation of synthetic TLR2 agonists with 
antigens produced strong adjuvant activity [21,22]. 
Improving the capability of poly tert-butyl acrylate to elicit a stronger immune response 
requires well understanding of its mode of action. Poly tert-butyl acrylate 1 is similar in its 
hydrophobicity to TLR2 agonists such as Pam2Cys, therefore we assumed that this receptor might be 
involved in recognition of the polymer.  
2. Materials and methods 
Compounds 2 [23], 3 [10], and 4 [23], were synthesized as previously reported. 
2.1. Synthesis of compound 1 
A mixture of Poly tert-butyl acrylate (3) (3 mg, 0.2 µmol, 1 equiv.) and biotin-J14-azide 4 (1.97 mg, 
0.4 µmol, 2 equiv.) was dissolved in DMF (1 ml), and a copper wire (60 mg) was added. The air in 
the reaction mixture was removed by nitrogen bubbling. The reaction mixture was covered and 
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protected from light with aluminum foil and stirred at 50 ℃ under nitrogen for 4 h. The wires were 
filtered off from the warm solution and washed with 1 ml of DMF. Millipore endotoxin-free  
water (7 ml) was slowly added to the solution (0.005 ml/min). Particles formed through the  
self-assembly process were exhaustively dialyzed against endotoxin-free water using presoaked and 
rinsed dialysis bags (Pierce Snakeskin, MWCO 3K). The yield of the reaction was 1.95 mg, 25%. 
The final formulation was self-assembled into particles in water with diameters 300–400 nm as 
observed by dynamic light scattering (DLS) using a Malvern Zetasizer Nano Series with DTS 
software. Size was analyzed using a noninvasive backscatter system. Multiplicate measurements 
were performed at 25 ℃ with a scattering angle of 173° using disposable cuvettes and the number-
average hydrodynamic particle diameter was reported. 
2.2. TLR expression 
The open reading frame (ORF) of TLR2 was obtained from the Diamantina Institute, UQ. The 
extracellular domain of TLR2 was expressed with mCherry fusion tag in vector pCellFree  
G08 [23,24]. TLR2 was expressed using the Leishmania tarentolae extract prepared as previously 
described [25,26]. Protein was resolved on NuPage Novex 4%–12% SDS-PAGE gel (Invitrogen, 
Australia) and scanned for fluorescence using the ChemiDoc MP System (Bio-Rad, Australia). 
Preheating gel samples to 72 ℃ instead of > 95 ℃ allows the mCherry fluorescence to persist in the 
SDS-Page gel, allowing expression size to be validated against the ORF size expected. TLR2 fusion 
protein showed its expected size (91 kDa). 
2.3. AlphaScreen proximity assay 
The extracellular domain of TLR2 fusion protein was expressed in L. tarentolae extract at 27 ℃ 
for 30 minutes. 2.5 μl of protein expression reaction was then mixed with an equal volume of serially 
diluted biotin-labeled compound 1 ranging from 100 nM to 50 μΜ. Expression reaction refers to the 
Leishmania tarentolae cell-free protein synthesis reaction, which expresses the TLR fusion protein. 
Then, protein expression was continued by incubation at 27 ℃ for an additional 2.5 hours. The 
resulting mixture was diluted 4 fold in buffer A (25 mM HEPES, 5 mM NaCl), followed by 3 more 
10-fold dilutions in buffer A. From each dilution, 2 μl was added to 12.5 μl of buffer B (0.32 μg/μl 
anti-cMyc acceptor beads, 25 mM HEPES, 50 mM NaCl, 0.001% (v/v) casein and 0.001% (v/v) 
Nonidet P-40), and incubated in the dark for 45 min to allow acceptor beads to couple with  
cMyc-tagged fusion protein. Subsequently, 0.4 μg of Streptavidin-coated donor beads in 2 µl of 
buffer A was then added to each dilution and incubated for 45 min in the dark. The AlphaScreen 
signal was measured with the Envision Multilabel plate reader (Perkin Elmer, Australia) according to 
the manufacturer’s recommended settings (excitation: 680/30 nm for 0.18 s, emission: 570/100 nm 
after 37 ms). For each concentration of compound 1, the maximal AlphaScreen signal was 
determined and plotted against the sample dilution. 
3. Results and discussion 
Here, we performed the first attempt to investigate the ability of poly tert-butyl acrylate to bind 
with TLR2 via the AlphaScreen assay and cell-free expression techniques. Pam2Cys is a potent 
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TLR2 agonist that was used both in vitro and in vivo as a self adjuvanting moiety [27,28]. In this 
study, Pam2Cys was used as a positive control. Polymer 1 and its Pam2Cys analogue 2 were tagged 
with a biotin moiety (Figure 1). For the attachment of the polymer 3 to J14 epitope, the azide 
derivative of biotin-J14 (4-biotin-KQAEDKVKASREAKKQVEKALEQLEDKVKGK(OCCH2N3)G) was 
synthesized by using solid phase peptide synthesis (SPPS) [23]. Compound 4 was then conjugated 
with the alkyne group on polymer 3 via the copper-catalyzed azide-alkyne cycloaddition (CuAAC) 
reaction to give the final compound 1 in 25% yield (Figure 2). The particle size diameter,  
300–400 nm, of the final formulation after self-assembly in water was measured by dynamic light 
scattering (DLS).  
 
Figure 1. Structures of poly tert-butyl acrylate-J14-biotin (1) and Pam2Cys-J14-biotin (2). 
The AlphaScreen assay was performed to test the affinity of compounds 1 and 2 toward the in 
vitro cell-free expressed extracellular domain of TLR2 [23]. The biotin tagged compounds 1 and 2 
were bound to a streptavidin-coated donor bead. Anti-cMyc acceptor beads recruited the TLR2 
through its cMyc tag. Upon excitation, the donor bead generated singlet oxygen with a half-life of 4 
μs and diffusive distance of ~200 nm. Interaction of the compounds (1 and 2) with TLR2 brought 
donor and acceptor beads into close proximity, which allowed the singlet oxygen to react with 
thioxene derivatives of the acceptor beads. This is turn stimulates luminescence which is detected as 
an AlphaScreen signal in counts per second (cps). As expected, the Pam2Cys analogue bound to 
TLR2 (Figure 3). In contrast, polymer 1 did not show any affinity to bind to TLR2 (Figure 3). This 
demonstrated that the ability of conjugate 1 to stimulate an immune response occurs through a 
different mechanism rather than binding to TLR2.  
 
145 
AIMS Allergy and Immunology  Volume 2, Issue 3, 141–147. 
4. Conclusion 
Finding the mode of action of poly tert-butyl acrylate may help in modulating the immunogenic 
activity of the polymer. Two biotin conjugates 1 and 2 were successfully designed and synthesized to 
investigate the affinity of poly tert-butyl acrylate toward TLR2. The extracellular domain of TLR2 
was successfully expressed by using the cell-free expression technique. The well-known TLR2 
agonist Pam2Cys 2 demonstrated a very strong binding to TLR2; however, the polymer analogue 1 
did not show any affinity by applying the AlphaScreen assay. Discovery of the mechanism of action 
of poly tert-butyl acrylate is still under progress. 
 
Figure 2. Synthesis of 1 through CuAAc reaction between the alkyne derivative of poly 
tert-butyl acrylate (3) and azide derivative of J14-biotin (4) in presence of copper wire 
and DMF at 50 ℃. 
 
Figure 3. Analysis of interactions of conjugates 1 and 2 with in vitro expressed TLR2 
using the AlphaScreen proximity assay. The AlphaScreen assay was performed at 10 nM 
concentration of cell-free expressed TLR2, while varying the concentrations (100 nM– 
50 μM) of 1 or 2.  
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